Berlin-headquartered Baze launched in 2018, opening an office in Boston and offering US consumers an at-home blood testing kit to measure an individual’s micronutrient levels. Data from the test is then used to recommend a set of monthly supplements.
Nature’s Way led the Series A fundraising round which totaled $6 million.
“Our investment in BAZE as a long-term strategic investment. Consumers are showing increased interest in personalized nutrition and it has always been the mission of Nature’s Way to help more people find a better way to wellness,” Nature’s Way president and CEO Mike Devereux told us.
“With consumers growing interest in personalized medicine and the unique technology that BAZE has pioneered, we see this as an attractive way to learn and grow.”
In a press release, Baze said the funds will “expand its marketing efforts to educate mass consumers on the importance of truly personalized supplements.”
We caught up with Baze co-founder and CEO Philipp Schulte last year.
Read the full story HERE
Company growth so far
Since its launch, the average growth rate of new US subscribers month-over-month has been 40%, Baze co-founder and CEO Philipp Schulte told us.